

## **Adult CIRB - Late Phase Emphasis Meeting Agenda**

**November 4, 2021**

---

### **I Continuing Review**

**A031704**, PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] (Protocol Version Date 08/26/21)

---

### **II Continuing Review**

**A041501**, A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL (Protocol Version Date 09/04/20)

---

### **III Continuing Review**

**EA6183**, A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D) (Protocol Version Date 08/02/21)

---

### **IV Continuing Review**

**EA8171**, Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer (Protocol Version Date 09/22/21)

---

### **V Continuing Review**

**EA9171**, BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD (Protocol Version Date 10/13/21)

---

### **VI Continuing Review**

**NRG-GY020**, A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer (Protocol Version Date 10/19/21)

## **VII Continuing Review**

**NRG-LU006**, Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy with or without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) (Protocol Version Date 01/02/20)

---

## **VIII Continuing Review**

**S1416**, Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer with or Without Brain Metastases (Protocol Version Date 04/02/21)

---

## **IX Continuing Review**

**S1914**, A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC (Protocol Version Date 05/28/21)

---

## **X New Study - Initial Review**

**A091903**, A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma (Protocol Version Date 10/21/21)

---

## **XI Amendment**

**A151804**, Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events (Protocol Version Date 09/27/21)

---

## **XII Amendment**

**RTOG-1308**, Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy For Inoperable Stage II-IIIB NSCLC (Protocol Version Date 10/06/21)

---